Development of 5‘ LTR DNA methylation of latent HIV-1 provirus in cell line models and in long-term-infected individuals
© Trejbalová et al. 2016
Received: 14 October 2015
Accepted: 10 February 2016
Published: 19 February 2016
Human immunodeficiency virus type 1 (HIV-1) latency represents the major barrier to virus eradication in infected individuals because cells harboring latent HIV-1 provirus are not affected by current antiretroviral therapy (ART). We previously demonstrated that DNA methylation of HIV-1 long terminal repeat (5’ LTR) restricts HIV-1 reactivation and, together with chromatin conformation, represents an important mechanism of HIV-1 latency maintenance. Here, we explored the new issue of temporal development of DNA methylation in latent HIV-1 5’ LTR.
In the Jurkat CD4+ T cell model of latency, we showed that the stimulation of host cells contributed to de novo DNA methylation of the latent HIV-1 5’ LTR sequences. Consecutive stimulations of model CD4+ T cell line with TNF-α and PMA or with SAHA contributed to the progressive accumulation of 5’ LTR DNA methylation. Further, we showed that once established, the high DNA methylation level of the latent 5’ LTR in the cell line model was a stable epigenetic mark. Finally, we explored the development of 5’ LTR DNA methylation in the latent reservoir of HIV-1-infected individuals who were treated with ART. We detected low levels of 5’ LTR DNA methylation in the resting CD4+ T cells of the group of patients who were treated for up to 3 years. However, after long-term ART, we observed an accumulation of 5’ LTR DNA methylation in the latent reservoir. Importantly, within the latent reservoir of some long-term-treated individuals, we uncovered populations of proviral molecules with a high density of 5’ LTR CpG methylation.
Our data showed the presence of 5’ LTR DNA methylation in the long-term reservoir of HIV-1-infected individuals and implied that the transient stimulation of cells harboring latent proviruses may contribute, at least in part, to the methylation of the HIV-1 promoter.
KeywordsHIV-1 Latent reservoir DNA methylation Chromatin conformation Latent HIV-1 provirus reactivation HIV-1-infected individuals
A combination of antiretroviral drugs is the current treatment used to suppress human immunodeficiency virus type 1 (HIV-1) replication in infected patients. Nevertheless, the virus persists in the patient’s cellular reservoirs, where it is able to establish latent infection. The major HIV-1 reservoir is a small pool of latently infected resting memory CD4+ T cells carrying an integrated form of the viral genome [1–4]. The latent reservoir impedes HIV-1 eradication from the organism because under the non-productive state of infection, HIV-1 is refractory to immune surveillance and eradication by antiretroviral therapy (ART). Although the process of latency establishment is not yet clear, the maintenance of the latent reservoir determines the outcome of the therapy. Mutually cooperating mechanisms in HIV-1 transcriptional latency include transcriptional interference, insufficient levels of cellular transcriptional activators, chromatin conformation, DNA methylation, influence of the integration site, and fluctuations in Tat protein expression.
Once latency is established, repressive chromatin around the HIV-1 5’ LTR is critical for the maintenance of latency [5–13]. Considerable efforts are underway to employ agents that induce chromatin de-repression or activation of transcription for HIV-1 reactivation in vivo in cells of the latent reservoir. It is believed that infected cells in which HIV-1 latency is reversed will be killed by the immune response or viral cytopathic effects whereas new rounds of infection will be prevented by ART [14–16]. Histone deacetylase (HDAC) inhibitors, including valproic acid (VPA) and suberoylanilide hydroxamic acid (SAHA, Vorinostat), have been used in attempts to purge the latent reservoir, but without ultimate success [17–23]. One clinical study reported reduction of the latent viral reservoir size in infected individuals receiving ART and VPA treatment . However, following clinical trials using VPA or SAHA failed to progressively reduce the frequency of infected resting CD4+ T cells [17, 18, 20–22, 25–31]. In agreement, it was demonstrated that HDAC inhibitors, including VPA and SAHA, do not induce HIV production in the latent viral reservoir of aviremic individuals in ex vivo system . In addition, other HDAC inhibitors, panobinostat and romidepsin, stimulated HIV-1 expression in latently infected primary cells , in CD4+ T cells ex vivo and also in HIV-1-infected individuals in vivo [34, 35]. In summary, the results of clinical trials have demonstrated that the latent reservoir in vivo is reactivated only partially, and the latency maintenance mechanisms are therefore crucial targets for HIV-1-therapeutic strategies (reviewed in ).
Another factor that cooperates with chromatin structure in HIV-1 latency maintenance is DNA methylation. A study by Kauder et al. identified two CpG islands flanking the HIV-1 transcription start site, the first CpG island located in the U3 region, the second CpG island overlapping the last nucleotide of the U5 region and 189 nucleotides downstream of the HIV-1 5’ LTR . Importantly, we and others have suggested that the DNA methylation of HIV-1 promoter/enhancer sequences is not involved in the establishment of latency but rather plays an important role in its maintenance [29, 37, 38]. We have shown previously in an in vitro model of HIV-1 latency and in a latent reservoir of HIV-1-infected patients that CpG methylation of the HIV-1 5’ LTR is an additional epigenetic restriction mechanism that controls the resistance of latent HIV-1 to reactivation signals and thus determines the stability of HIV-1 latency. However, we have shown that methylated proviruses can be reactivated to some extent using inhibitors of histone deacetylases and inhibitors of DNA methylation . In this context, the DNA methylation levels of HIV-1 5’ LTR in the latent reservoir in vivo are highly important.
The methylation status of the 5’ LTR in patients was addressed in several studies with different outcomes. In our previous study, we analyzed the memory CD4+ T cells of six aviremic HIV-1-infected individuals who were treated for 11.5 years (median), and we detected 19 to 100 % CpG methylation in the 5’ LTR . In the following studies, only 1 and 2 % of methylated CpGs in HIV-1 5’ LTR were detected in the resting CD4+ T cells of patients who were treated for 2.9 and 5 years, respectively [39, 40]. Moreover, the peripheral blood mononuclear cells (PBMCs) of long-term non-progressors displayed 0 and 5 % methylated CpGs in the HIV-1 5’ LTR [41, 42]. Overall, the assessments of the HIV-1 5’ LTR methylation levels in the latent reservoir of ART-treated HIV-1-infected individuals remain controversial and require further exploration.
In this study, we focused on the development of 5’ LTR DNA methylation in latent HIV-1. To explore this phenomenon, we took advantage of the latency cell line model that was validated in our previous study. We employed two Jurkat-derived cellular clones, H12 and 2D12, which harbor a latent HIV-1 “mini-provirus” (LTR-Tat-IRES-EGFP-LTR) whose reactivation can be monitored according to the percentage of EGFP-positive cells . Both clones used in the previous and present study contained an identical and genetically unaltered single proviral copy that was integrated at the same site of the human genome within the intron of ubiquilin 1 gene. As we had shown previously, clone H12 displayed a low level of HIV-1 5’ LTR DNA methylation of the first CpG island (7 %), and the latent provirus was easily reactivated by various latency-reversing agents . In contrast, clone 2D12 displayed a high level of 5’ LTR DNA methylation of the first CpG island (95 %), and the latent provirus was resistant to reactivation . Importantly, the 2D12 clone was derived from H12 cells by mitogenic phorbol-12-myristate13-acetate (PMA) and tumor necrosis factor-α (TNF-α) stimulation and the subsequent selection of EGFP-negative subclones . We showed that DNA methylation in the HIV-1 5’ LTR accumulated in the course of cell line stimulation by NF-κB inducers and selection of EGFP-negative cells.
To study the temporal development of DNA methylation of HIV-1 promoter we investigated whether the stimulation of Jurkat-derived latency model cell line harboring the HIV-1 provirus can induce DNA methylation of the 5’ LTR. We showed in this model that repeated transient stimulations of cells assisted de novo 5’ LTR DNA methylation of the latent HIV-1 provirus. However, the high DNA methylation level of the latent 5’ LTR was a stable epigenetic mark. Finally, we measured 5’ LTR DNA methylation in the latent reservoir of HIV-1-infected individuals who were treated for various periods of time. We demonstrated accumulation of DNA methylation in HIV-1 5’ LTR in the latent reservoir of HIV-1-infected individuals with a long history of ART. Our data showed that although HIV-1 5’ LTR methylation in the resting CD4+ T cells of HIV-1-infected individuals was a rare event, it increased with the time of reservoir persistence. Our results suggest that transient cellular stimulations may contribute, at least partially, to increase of 5’ LTR DNA methylation in the HIV-1 latent reservoir and, therefore, may contribute to the reservoir stability.
Cellular stimulation contributed to de novo DNA methylation of the proviral 5’ LTR in the cell line model
First, we reproduced the previously mentioned experiment using FACS-sorting of the EGFP-negative pool of H12 cells that contained non-activated latent provirus. After the first 24-h stimulation of the H12 cell line with TNF-α and PMA, the HIV-1 latent provirus was reactivated in 79 % of the cells. We sorted the remaining 21 % of EGFP-negative cells and let the cells restore to their non-stimulated steady state. We then repeated the stimulation with TNF-α and PMA and sorted the EGFP-negative cells (Fig. 1a). After the third cycle of stimulation, the latent provirus was reactivated in only 25 % of the cells (Fig. 1b). Simultaneously, the 5’ LTR methylation of the latent provirus as measured by bisulfite sequencing increased from 7 % of methylated CpGs before the first stimulation and sorting to 68 % after the third cycle of stimulation (Fig. 1c).
In parallel, we performed a series of consecutive stimulations of H12 cells without sorting the EGFP-negative cells. After the first 24-h stimulation of H12 cells with TNF-α and PMA, the HIV-1 latent provirus was reactivated in 82 % of the cells. We let the entire population of cells containing both reactivated and non-activated HIV-1 proviruses restore to the latent EGFP-negative steady state. We repeated this procedure five times (Fig. 1a). After the fifth cycle of stimulation, the latent provirus was reactivated only in 68 % of the cells (Fig. 1b). Simultaneously, the 5’ LTR methylation of the latent provirus increased from 7 % of methylated CpGs before the first stimulation to 34 % before the fifth stimulation (Fig. 1c). The results showed that accumulation of 5’ LTR DNA methylation did not require selection of EGFP-negative cells. To gain deeper insight into the mechanism of 5’ LTR DNA methylation accumulation we analyzed the individual 5’ LTR molecules within the methylation profile of the H12 cells before the fifth stimulation showing the average level of 34 % methylation (Fig. 1d). The majority of individual 5’ LTR molecules contained less than 50 % DNA methylation, arguing against the selection of preexisting non-reactivated methylated molecules (Fig. 1e). In a parallel culture of non-stimulated H12 cells, the hypomethylated status of the HIV-1 promoter remained stable (7 %). Our results noted that cellular stimulation with TNF-α and PMA supported de novo CpG methylation in the 5’ LTR of both reactivated and non-activated proviruses. Repeated cellular stimulations contributed, at least in part, to the progressive accumulation of DNA methylation in the latent HIV-1 promoter.
In contrast to progressive methylation of the initially hypomethylated latent promoter, the DNA methylation of highly methylated 2D12 5’ LTR remained stable after consecutive activations (Additional file 1: Figure S1A). We used the same repeated cycles of the 2D12 cells stimulation with TNFα and PMA. Surprisingly, we did not observe any continuous increase in the percentage of EGFP-positive 2D12 cells during this experiment, even after the sorting of EGFP-positive cells (Additional file 1: Figure S1B). In accordance, we did not detect decrease of 5’ LTR DNA methylation levels. Repeated cycles of cellular stimulation by NF-κB inducers did not alter the hypermethylated status of HIV-1 5’ LTR in the 2D12 cells.
Thus, we demonstrated that repeated stimulation cycles of Jurkat-derived CD4+ T cells harboring the latent HIV-1 provirus contributed to de novo CpG methylation within the 5’ LTR. The density of CpG methylation in the latent HIV-1 promoter increased gradually with the number of cell stimulation cycles even without the selection of EGFP-negative cells, although at a lower rate than in the selected population. The increase in the 5’ LTR DNA methylation level correlated with a decreased reactivation capacity of the latent provirus by NF-κB inducers. Furthermore, once established, the high DNA methylation level of the HIV-1 5’ LTR remained stable and resistant to demethylation.
Both TNF-α-PMA and SAHA stimulation increased DNA methylation of the latent HIV-1 5’ LTR in the model cell line
In addition to the average DNA methylation, the level of CpG methylation of individual HIV-1 promoters could serve as a hallmark of proviral activity. In Fig. 2b, we showed the distribution of 5’ LTR molecules with increasing counts of methylated CpG dinucleotides within each molecule. In the non-stimulated culture of H12 cells, the HIV-1 promoter sequences with one methylated CpG were the most prevalent whereas 5’ LTR sequences with two or three methylated CpGs were rare (Fig. 2b). In contrast, in H12 cells stimulated with TNF-α and PMA, HIV-1 promoters with seven methylated CpGs prevailed, and many 5’ LTR molecules contained at least nine methylated CpGs out of 14 CpG dinucleotides (Fig. 2b). In H12 cells that were stimulated with SAHA, the distribution of methylated CpG was bimodal; this group of promoters showed a hypomethylated peak with one, two, or three methylated CpGs and another peak with five or six methylated CpGs, the maximal level being eight methylated CpGs in one molecule (Fig. 2b). In conclusion, a new category of 5’ LTR molecules with densely methylated CpGs were present in the TNF-α and PMA-stimulated EGFP-negative cell population in comparison with the non-stimulated cells.
Finally, we analyzed the patterns of 5’ LTR DNA methylation. The DNA methylation levels at the individual CpG dinucleotides (Fig. 2c) were significantly different at seven CpGs in TNF-α and PMA-stimulated H12 cells compared to SAHA-stimulated H12 cells. We observed an intriguing situation at the NF-κB binding site concerning CpG nos. 6 and 7. CpG no. 6 was the only one of 14 CpGs that did not display increased DNA methylation after any type of cell stimulation. DNA methylation at CpG no. 7 was significantly increased in latent proviruses after stimulation with TNF-α and PMA but not after stimulation with SAHA (p < 0.01).
In summary, we have shown that stimulation of CD4+ T cells with both TNF-α and PMA or SAHA followed by EGFP-negative cell selection induced a significant accumulation of DNA methylation at the 5’ LTR of the latent HIV-1 provirus. In accordance with more efficient cellular stimulation, TNF-α and PMA contributed to significantly higher DNA methylation of the 5’ LTR than the SAHA treatment.
Hypermethylation of 5’ LTR DNA in the HIV-1 latency model cell line is maintained by DNMT1
Assuming the role of provirus 5’ LTR DNA methylation in the maintenance of HIV-1 latency, we explored the stability of HIV-1 5’ LTR hypermethylation in the 2D12 cell line. We knocked down the expression of DNA methyltransferase 1 (DNMT1) by siRNA (siDNMT1) and analyzed the effect of DNMT1 knockdown on the HIV-1 provirus reactivation by NF-κB inducers and its 5’ LTR DNA methylation level.
We estimated the changes in the 5’ LTR methylation level as a direct effect of the DNMT1 knockdown. Using bisulfite sequencing, no decrease in the 5’ LTR methylation was observed after siCTRL transfection. We detected a mild decrease of 5’ LTR CpG methylation in 2D12 cells after the DNMT1 knockdown. The 5’ LTR DNA methylation was reduced by 17 % 6 days after transfection of siDNMT1 (p < 0.001; Fig. 3c).
These results show that the high methylation level of the latent 5’ LTR is partially reduced in cells with DNMT1 depletion. However, we observed no effect of DNMT3B depletion, suggesting a role for DNMT1 in the maintenance of 5’ LTR hypermethylation in the 2D12 model cell line. In accordance with our previous results, the reduction of the 5’ LTR methylation level of the provirus correlated with the increased reactivation capacity of the latent HIV-1 after activation with TNF-α and PMA.
5’ LTR DNA methylation is resistant to HDAC2 depletion in the HIV-1 latency model cell line
The HDAC1 knockdown did not exert any effects on provirus reactivation in either the non-stimulated or in stimulated 2D12 cells (Fig. 5c). The HDAC2 knockdown did not induce latent provirus reactivation in non-stimulated 2D12 cells (Fig. 5c, left column). However, 6 days after transfection TNF-α and PMA stimulation reactivated the latent provirus in 46 % of 2D12 cells with knocked down HDAC2 compared to 34 % of siCTRL-transfected cells or 30 % of non-transfected 2D12 cells (p < 0.01; Fig. 5c, right column). We did not observe any significant decrease in the proviral 5’ LTR DNA methylation level after HDAC2 knockdown in the 2D12 cell line. The 2D12 cells that were transfected with siRNAs targeting HDAC2 displayed 94 % methylated CpGs in the 5’ LTR, which was comparable with the 92 % that was found in 2D12 cells transfected with control siRNA (Fig. 5d).
In accordance with our previous findings showing the importance of both DNA methylation and chromatin deacetylation for HIV-1 latency maintenance, the depletion of HDAC2 led to the partial reactivation of the HIV-1 provirus with a hypermethylated 5’ LTR after TNF-α and PMA stimulation. However, in our CD4+ T cell line model, we observed no effect of HDAC2 knockdown on the methylation level of the latent HIV-1 provirus 5’ LTR, which remained stable.
DNA methylation of HIV-1 5’ LTR in the latent reservoir of ART-treated patients
The 5’ LTR methylation profile was exemplified by individual no. 10 with 8 % of 5’ LTR methylation (Fig. 6b). None of the analyzed patients contained more than two methylated CpGs in one 5’ LTR molecule. This indicated that highly methylated proviral molecules, which are expected to be resistant to reactivation, do not accumulate in the latent reservoir of patients who are treated for up to 3 years. The positions of the methylated CpGs within the 5’ LTR did not show any site-specific patterns. In some individuals, we observed polymorphisms of the 5’ LTR sequences including mutations of individual CpG dinucleotides. For example, all 5’ LTR sequences of patient no. 10 lacked the third CpG (Fig. 6b). Mutations in the 5’ LTR may generate defective proviruses. Such proviruses were shown to be preferentially methylated. However, we detected low methylation levels of proviruses with altered CpG dinucleotide patterns.
In addition, we determined CpG methylation within the envelope coding region comprising a CpG island that does not contribute to the regulation of viral transcription . Three HIV-1-infected individuals displayed variable levels of DNA methylation ranging from 8 to 75 % CpG methylation in resting CD4+ T cells showing that analyzed HIV-1 DNA can be methylated (Fig. 6c). It also suggests that HIV-1 proviruses are subjected to the DNA methylation in infected individuals, but are protected within the region important for transcriptional regulation.
Taken together, and in agreement with previous reports, we found low methylation levels of HIV-1 5’ LTR in the latent reservoir of infected individuals who were treated for a maximal period of 35 months.
DNA methylation of HIV-1 5’ LTR in the latent reservoir of patients with a long history of ART
In summary, long-term ART contributed to the accumulation of CpG methylation in 5’ LTR in the HIV-1 latent reservoir. Furthermore, densely methylated 5’ LTR molecules could be found within the latent reservoirs of patients with a long history of ART. Our results in infected individuals are also supported by the progressive increase of 5’ LTR CpG methylation in the Jurkat cell line model.
Our results from the T cell model of HIV-1 latency showed that repeated transient stimulations of cells with TNF-α and PMA, which occurred via PKC and NF-κB and caused efficient T cell activation [43–45], contributed, at least partially, to de novo DNA methylation of the 5’ LTR. Furthermore, stimulation with SAHA, which did not cause global activation of resting T cells [32, 33], also supported accumulation of DNA methylation of the 5’ LTR, although at a lower rate than TNF-α and PMA stimulation. It should be noted, however, that in contrast to the reservoir of infected individuals, our Jurkat-derived model cell lines H12 and 2D12 harbored the HIV-1 mini-virus. Nevertheless, in our present work, we observed the long-term accumulation of 5’ LTR DNA methylation in the latent reservoir of HIV-1-infected individuals. In the group of 10 long-term-treated patients, we detected four individuals with 10 to 45 % methylated CpGs in the latent HIV-1 5’ LTR. We suggest that 5’ LTR DNA methylation may accumulate in rare proviral copies in the latent reservoir of HIV-1-infected individuals as a result of transient stimulations of reservoir cells.
Accumulation of 5’ LTR DNA methylation in vivo as a result of transient stimulations of reservoir cells could, paradoxically, be provoked by therapeutic reactivation approaches. However, exact mechanism of accumulation of DNA methylation in the latent reservoir of HIV-1-infected individuals is not clear. The high concentration of deamination-prone methylcytosines in the proviral 5’ LTR may lead to the higher mutation rates in the latent promoter. This mechanism may render the provirus defective for replication, or it may relieve transcriptional silencing .
Accumulation of the methylated 5’ LTR sequences in the stimulated H12 cells and in the long-term reservoir of HIV-1-infected individuals is compatible with de novo methylation of the HIV-1 promoter or with selective survival of cells bearing profoundly latent, methylated proviruses. It was recently estimated in vivo that antigenic or weak random stimulation of the host cells initiates viral replication in the HIV-1 reservoir once every 5–8 days . A limited number of stimulated HIV-1 reservoir cells can survive and possibly restore the resting phenotype [48–50]. Thus, according to both proposed mechanisms the CD4+ T cell stimulation-mediated accumulation of 5’ LTR DNA methylation would be a rare event, increasing its probability with the time of the HIV-1 reservoir persistence.
Specifically, in the Jurkat-derived model cell line, the subset of stimulated H12 cells that harbored the reactivated provirus could be selectively destroyed by cytotoxic effects of the viral protein products, TAT, or even EGFP. In this case, the increase in 5’ LTR DNA methylation levels would not be caused by de novo CpG methylation but rather by selection for preexisting non-reactivable hypermethylated proviral 5’ LTRs that would lack expression of the viral proteins. To gain deeper insight into the situation, we compared the 5’ LTR methylation profiles of the H12 cells after consecutive series of TNF-α and PMA stimulations performed with or without selection of EGFP-negative cells. The methylation profile of 5’ LTR in the H12 cells without selection of EGFP-negative cells (mean percentage 34 % CpG methylation) did not display prevalence of hypermethylated molecules (Fig. 1d); the majority of 5’ LTR molecules contained less than half of methylated CpGs per molecule (Fig. 1e). In contrast, the H12 cells that went through the selection of EGFP-negative cells displayed the majority of highly methylated 5’ LTR molecules (Fig. 2b, middle panel) that would be anticipated in the case of selection of the preexisting hypermethylated molecules. We suggest that in the H12 model cell line, de novo methylation of the 5’ LTR after cellular stimulations with TNF-α and PMA contributes, at least in part, to the progressive accumulation of the 5’ LTR DNA methylation.
Significant alterations of the DNA methylation landscape and chromatin conformation at the genome-wide level occur during T cell stimulation, differentiation and development. Recent study showed that both DNA demethylation and de novo methylation events occurred throughout the maturation of human thymocytes although DNA demethylation prevailed over de novo methylation. Furthermore, DNA methylation changes in a particular CpG site took place generally only once during development of thymocytes and were stable in subsequent differentiation stages . In mouse model, more than 1100 differentially methylated regions were identified comparing naïve and memory CD4+ T cells exposed to specific antigen demonstrating a link between T cell methylation status and T cell differentiation . Analysis of unstimulated naïve and memory CD4+ cells from human healthy donors showed that CD4+ memory T cells were hypomethylated compared with naïve cells . Another survey demonstrated that global DNA demethylation occurred rapidly (within 6 h) in mouse CD4+ T cells following their activation with PMA/Ionomycin . On the other hand, immune activation of human naïve CD4+ T cells with anti-CD3/CD28 did not reveal any significant changes in DNA methylation of the promoter regions within 48 h of activation  despite reports suggesting that such changes occur in several genes, including IL2 and IFNγ [55–57]. Furthermore, it was showed that there is a very rapid and reversible increase in global CpG methylation after PHA/IL-2 stimulation of human PBMCs . Thus, remodeling of the methylation landscape appears to occur throughout CD4+ T cells differentiation and following CD4+ T cells activation. It is believed that MBD proteins play a central role in the cellular readout of DNA methylation. Methyl-CpG binding protein 2 (MBD2) is thought of as a reader of the mCpG signature that recruits or associates with the NuRD co-repressor complex containing histone deacetylases, which in turn reinforces transcriptional silencing [59, 60].
Inhibitors of HDAC were reported to have various effects on the global DNA methylation. Inhibitor of DNA methyltransferases, decitabine, and inhibitor of HDAC, SAHA, were demonstrated to target distinct and non-overlapping regions of the genome in the human colorectal cell lines . Another HDAC inhibitor, romidepsin, had essentially no effects on global DNA methylation of the human lymphoma cell lines . On the other hand, treatment of porcine somatic cell nuclear transfer embryos with HDAC inhibitor oxamflatin downregulated DNMT1 expression and global DNA methylation level in two-cell-stage embryos . Finally, VPA inhibition of HDAC increased global DNA methylation in human neuroblastoma cell lines .
Our results demonstrated that stimulation of the model cell line with TNF-α and PMA or with SAHA contributed to de novo DNA methylation of the 5’ LTR. Several studies in a human cell line or mouse model manifested an unconventional role of NF-κB as a transcriptional repressor that mediated DNA methylation by recruiting DNMT1 or DNMT3B to the target DNA sequence [65–67]. The recruitment of DNA methyltransferases via NF-κB would offer a possible mechanism for the accumulation of 5’ LTR DNA methylation after TNF-α and PMA treatment.
We demonstrated that the depletion of DNMT1, but not DNMT3B, contributed to a partial loss of 5’ LTR methylation in the 2D12 cell line. Accordingly, in the mouse model, it was suggested that DNMT1-dependent methylation activity, in contrast to DNMT3B, was essential for maintaining methylation and suppressing retrotransposon LTRs [68, 69]. We did not test the effect of DNMT3A depletion on 5’ LTR methylation. Previous study from our laboratory using avian leucosis/sarcoma virus-based reporter vector showed that absence of DNMT3A resulted only in a slight additional decrease of silencing efficiency in comparison with the knockout of DNMT3B alone and DNMT3A scored weaker than DNMT3B in silencing rescue experiments . In addition, DNMT3A was established to be recruited by H3K36 me3 histone modification that was enriched in exon regions compared to introns [71, 72], and we have previously localized the HIV-1 mini-provirus in the 2D12 cell line within the intron of UBQLN1 (ubiquilin 1) gene .
It was observed in CD4+ T cell lines and in the primary T cell model of HIV-1 latency that MBD2 is recruited to the second, but not to the first, CpG island of HIV-1 promoter. Together with MBD2, the HDAC2 was recruited to the second CpG island. Further, inhibition of DNA methylation reduced the methylation level of both CpG islands and abrogated the recruitment of MBD2 and HDAC2, resulting in partial transcriptional reactivation . In our experiments, depletion of HDAC2 in the 2D12 cell line induced partial reactivation of the HIV-1 provirus by NF-κB inducers without changing DNA methylation level of the first CpG island. Consistently, in our previous work, we showed that the levels of histone 3 acetylation in the HIV-1 5’ LTR in 2D12 cell line increased 2.3-times after TNF-α and PMA stimulation .
We and others have shown previously that HIV-1 5’ LTR DNA methylation in combination with the chromatin structure of the latent HIV-1 5’ LTR tightly controls reactivation of the provirus. Although the latent provirus with highly methylated 5’ LTR can be reactivated, the efficiency of reactivation was lower than for the provirus with hypomethylated 5’ LTR. After the provirus reactivation in vivo, the majority of host cells are believed to be eliminated by the viral cytopathic effect or by the immune system. In fact, we detected populations of hypermethylated molecules that were present at a low frequency in the latent reservoir of HIV-1-infected individuals who were treated for long periods of time. Reactivation-resistant hypermethylated proviral molecules in the latent reservoir would thus facilitate long-term survival of the host cells and would represent the fraction of the latent reservoir with long-term stability.
Furthermore, the hypermethylated provirus could be replicated during homeostatic proliferation of cells of the HIV-1 latent reservoir [73–75]. Clonal expansion of certain proviral populations of the latent reservoir, including CD4+ memory cells, was shown to increase with the time spent on ART [76–78]. In the present study, after the long-term persistence of the HIV-1 reservoir, we observed populations of highly methylated molecules and of non-methylated molecules within the same patient (nos. LT1, LT5, LT10), suggesting the possibility of clonal expansion of hypermethylated 5’ LTR populations.
Importantly, an analysis by Cohn et al.  demonstrated that the majority of clonally expanded integrated proviruses are defective and contain mainly deletions or mutations of the 5’ LTRs. However, Maldarelli et al.  showed that a highly expanded clone of cells produced HIV virions in sufficient quantity to cause viremia. In our study, we did not find mutations of CpG dinucleotides, rearrangements, or polymorphisms to occur preferentially in highly methylated versus non-methylated 5’ LTR sequences from HIV-1-infected individuals.
It was observed recently that over 10 % of the integrated latent proviruses in patients could not be reactivated by stimulation of T cells harboring HIV-1. Importantly, the reactivation-resistant fraction of the latent reservoir was reported to lack inactivating mutations or promoter DNA methylation and was not integrated into transcriptionally silent regions . However, in the mentioned study, only six patients who were treated for 6 years were analyzed for 5’ LTR DNA methylation . Although stochastic fluctuations of transcription factors were suggested to play a role in the reactivation of the latent HIV-1 reservoir , we speculate that the 5’ LTR DNA methylation of the small population of latent HIV-1 molecules may further limit the reactivation capacity of the fraction of the latent reservoir.
In our previous study , we reported increased 5’ LTR methylation levels in memory CD4+ T cells of six aviremic HIV-1-infected individuals. The patients were treated for a period of 4–17 years (median 11.5 years). More recently, Blazkova et al.  reported that the median frequency of methylated CpGs within the HIV-1 5’ LTR was only 2.4 % (range 0–10 %). The resting CD4+ T cells of 11 aviremic patients who were on therapy for a median of 2.9 years (maximum 6.6 years) were analyzed in this case . Both studies used the same technique of bisulfite sequencing. One of the sources of variability between the studies may lie in the different lengths of ART treatment. In the present survey, we analyzed the HIV-1 latent reservoir in two cohorts with different durations of treatment; the median treatment period was 2.3 years for the first cohort and 12.5 years for the second cohort. Intriguingly, in the cohort of patients who were treated for the shorter period of time, we detected 0 to 8 % CpG methylation in the 5’ LTR, whereas in the long-term-treated cohort, the level reached 0 to 45 % methylated CpGs. We propose that the accumulation of 5’ LTR DNA methylation may be observed in patients on ART with a long-term evolution of the latent reservoir.
Other sources of variability in the methylation levels of the HIV-1 latent reservoir could lie in the different characteristics of patients and different ART regimens. No significant difference in the plasma viral charge was detected in the present report between the group of HIV-1-infected individuals treated for up to 3 years and the long-term treated individuals (Tables S1 and S2). Patients from the study  showing high methylation levels of the latent HIV-1 5’ LTR were treated by an inefficient therapy regimen at the beginning. The same was true for patients from the long-term-treated cohort in our present report. We speculate that the inefficient ART regimen may influence the accumulation of DNA methylated proviruses in the reservoir indirectly, e.g., by affecting the reservoir size. However, to calculate the impact of other clinical parameters, a larger cohort of patients needs to be evaluated.
The mechanisms of HIV-1 latency maintenance are of crucial importance for therapeutic outcomes. So far, various efforts to activate the latent provirus using VPA or SAHA have been insufficient to reduce the latent reservoir size. In the present study, we focused on the role of 5’ LTR DNA methylation in long-term HIV-1 latency. We observed de novo appearance and gradual accumulation of 5’ LTR DNA methylation in the latent provirus 5’ LTR in an in vitro cell line model after successive stimulations of cells. Importantly, we confirmed the presence of limited numbers of highly methylated HIV-1 proviruses in the latent reservoir of patients after long-term persistence. We speculate that the long-term development of HIV-1 promoter methylation in the latent reservoir of infected patients contributes to reservoir persistence under ART treatment. Furthermore, we speculate that therapeutic attempts to activate the HIV-1 latent reservoir would contribute, at least in part, to an increase of 5’ LTR DNA methylation of certain latent HIV-1 proviruses resulting in an increase of reservoir stability.
We have shown before that 5‘LTR DNA methylation of HIV-1 promoter stabilizes the latent state and limits the reactivation of the provirus. Here, we focused on temporal development of DNA methylation in HIV-1 promoter. We demonstrated that stimulation of model CD4+ T cell line with TNF-α and PMA or with SAHA contributed, at least in part, to accumulation of DNA methylation of the HIV-1 promoter. We further showed that accumulation of 5‘LTR DNA methylation occured also in the resting CD4+ T cells of HIV-1-infected individuals characterized by the long-term existence of the latent reservoir. Further, a limited fraction of the long-term latent reservoir within some patients contained the highly methylated HIV-1 promoters that could represent the reactivation-resistant fraction of the latent reservoir. We speculate that the stimulation of cells harboring the latent HIV-1 provirus may contribute to increase of DNA methylation level of the HIV-1 promoter and therefore may contribute to the persistence of the reservoir.
This study was conducted according to the principles expressed in the Declaration of Helsinki. Each patient provided informed written consent to participate in this study in accordance with institutional and regulatory guidelines. The study was approved by the Ethics Committee of the Hospital Na Bulovce in Prague.
Seropositive individuals were selected for the study on the basis of the length of ART treatment and low viral load (<320 HIV-1 RNA copies per milliliter of plasma as determined with COBAS AmpliPrep/COBAS TaqMan HIV-1 Test, version 2.0, Roche).
Cell culture and stimulation
The H12 cell line was kindly provided by E. Verdin. The cell line was described previously . The 2D12 cell line was prepared by stimulation of the H12 cell line with TNF-α and PMA and subsequent single-cell sorting of EGFP-negative cells and clonal selection .
Cells were grown in RPMI 1640 medium containing 2 mM L-glutamine (Sigma-Aldrich) supplemented with 10 % fetal bovine serum, 100 U/ml penicilin and 100 μg/ml streptomycin at 37 °C under a 95 % air/5 % CO2 atmosphere. To reactivate the HIV-1 provirus, we treated the cell lines with 10 nM PMA (Sigma-Aldrich) and 10 ng/ml TNF-α (Sigma-Aldrich) or with 0.5 μM SAHA (Sigma-Aldrich) for 24 h. Reactivation was assayed immediately after the 24 h of treatment.
Flow cytometry analysis
We analyzed EGFP-positive and anti-CD69-phycoerythrin-labeled (Miltenyi Biotec) viable cells that were negative for staining with Hoechst 33258 (Invitrogen) at 1 μg/ml with an LSRII flow cytometer (BD Biosciences). Further analysis of flow cytometry data was carried out using FlowJo software.
EGFP-negative cells were isolated using an Influx high-speed cell sorter (BD Biosciences).
Specific ON-TARGETplus SMARTpool siRNAs against DNMT1, DNMT3B, HDAC1 and HDAC2 genes, along with a negative control, ON-TARGETplus Non-targeting siRNAs, were purchased from Dharmacon (GE Healthcare Life Sciences). The Lipofectamine RNAiMAX transfection reagent (Life Technologies) was used for siRNA transfection. The amount of 6 × 105 2D12 cells were seeded into 6-well plates and mixed with the siRNA-complex consisting of 90 pmol of specific siRNA SMARTpool or non-targeting negative control- and the lipofectamine RNAiMAX transfection reagent. Three or 6 days after the transfection, the cells were collected to analyze the efficiency of knockdown by Western blot analysis, relative quantitative RT-PCR, or to perform TNF-α and PMA stimulations and DNA isolations. Transfection efficiency was assessed to be 40 % according to the transfection efficiency of FITC-labeled BLOCK-iT™ Fluorescent Oligo (Invitrogen).
Western blot analysis
Thirty micrograms of total protein was loaded on 8 % SDS polyacrylamide gel and transferred to polyvinylidene difluoride membrane, which was consequently blocked in 5 % BSA. The membrane was then probed with 1:1000 dilution of Anti-DNMT1 antibody [EPR3522] (ab92314) (Abcam) or 1:250 dilution of anti-DNMT3B antibody [52A1018] (Abcam), HRP-conjugated secondary anti-rabbit antibody (Cell Signaling Technology), and anti-mouse antibody (Cell Signaling Technology). The luminescent reaction was conducted using LumiGLO (Cell Signaling Technology). Equal protein loading and transfer was verified by monoclonal Anti-γ-Tubulin, Clone GTU-88 (Sigma-Aldrich) on the same membrane.
Total RNA was isolated from approximately 2 × 106 cells using RNAzol RT (Molecular Research Center, Inc.). One microgram of total RNA was reverse-transcribed using random primers (Promega) and ProtoscriptII Reverse Transcriptase (New England BioLabs). Gene expression was then evaluated by relative quantitative RT-PCR (qRT-PCR) using the MESA GREEN qPCR Master Mix Plus for SYBR Assay (Eurogentec) in a C1000 Touch thermal cycler (Bio-Rad). See Additional file 9: Table S3 for the primer sequences. All reactions were run in triplicate, and the average Cts were used for quantitation. Signals were normalized to the corresponding RNA polymerase II, polypeptide A (POLR2A) housekeeping gene controls. The relative quantification of the target genes was determined using the ∆∆Ct method. The negative controls contained water instead of a template. All quantitative RT-PCRs were performed in triplicates. Data analysis was conducted with the aid of the CFX Manager software version 3.1 (Bio-Rad).
Preparation of resting and memory CD4+ T cells from PBMCs of HIV-1-infected patients
Patients’ PBMCs were separated using a BD Vacutainer CPT™ Cell Preparation Tube (BD Medical). PBMCs were separated by density gradient centrifugation of blood samples. Separated PBMCs were washed twice with PBS and used for further preparation. CD4+ T cells were separated from PBMCs by means of CD4+ T Cell Isolation Kit (Miltenyi Biotec). Non-CD4+ cells were labeled using a cocktail of biotin-conjugated antibodies (against CD8, CD14, CD15, CD16, CD19, CD36, CD56, CD123, TCRγ/δ, and CD235a). Subsequently, non-CD4+ cells marked with biotin were magnetically labeled with anti-biotin microbeads. CD4+ T cells were isolated by depletion of magnetically labeled cells. In the second step, the activated CD4+ T cells were labeled for activation markers with anti-CD25-PE, anti-CD69-PE, and anti-HLA-DR-PE (all Miltenyi Biotec). Marked cells were magnetically labeled with anti-PE microbeads. Resting CD4+ T cells were isolated by depletion of magnetically labeled activated CD4+ T cells. The purity of resting CD4+ T cells determined by FACS analysis was greater than 95 %. Memory CD4+ T cells were separated from PBMCs in one step by means of a Memory CD4+ T cell Isolation Kit (Miltenyi Biotec). Naive CD4+ T cells and non-CD4+ T cells were magnetically labeled using a cocktail of biotin-conjugated antibodies and anti-biotin microbeads. Isolation of memory CD4+ T cells was achieved by depletion of magnetically labeled cells.
Bisulfite cytosine methylation analysis
The samples of total genomic DNA from patients‘ resting or memory CD4+ T cells or from the H12 and 2D12 cells were isolated using proteinase K, RNase A, phenol-chloroform extraction and ethanol precipitation. Two micrograms of genomic DNA was used for bisulfite conversion using Epitect Plus DNA Bisufite Kit (Qiagen Inc.) and eluted in a total of 25 μl of water. Bisulfite-treated DNA was amplified by nested PCR specific for the 5‘LTR in a 50-μl reaction mixture. The first PCR round was performed with approximately 120 ng of genomic DNA; 2 μl from the first round was used for the second round. See Additional file 10: Table S4 for the primer sequences. The sense primers contained T and the antisense primers A instead of C in positions complementary to non-methylable C (i.e., C out of CpG dinucleotides). Cycling conditions are described in Additional file 11. At least three primary PCRs were performed for each sample to exclude amplification of one template molecule. Taking into account that approximately one resting CD4+ T cell out of 100–1000 contains integrated HIV-1 provirus, we placed about 10–100 proviruses into each PCR amplification. However, bisulfite treatment is known to cause significant fragmentation of DNA and the final number of template proviral molecules in one primary PCR reaction should be <10–100. Ten proviral templates represented the approximate detection threshold of bisulfite conversion followed by nested PCR as determined by dilution of the genomic DNA isolated from the H12 cell line. Non-converted DNA did not provide bands. Several non-template controls were included in each bisulfite PCR reaction. Amplification products were cloned in the pGEM-T-EasyVector System (Promega, Madison, WI) and sequenced. Analysis was performed using the Quma (Quantification tool for Methylation Analysis) software http://quma.cdb.riken.jp/. Only PCR clones with at least 95 % conversion of cytosines outside CpGs were taken into account. When more converted molecules with identical sequences were obtained, only one was used for calculation of the methylated CpG percentage to minimize the bias originating from the preferential amplification of one molecule.
Statistical analysis of continuous data was performed using Kruskal-Wallis non-parametric test (GraphPad Prism 5.04 software), the non-paired Student’s t test, and Mann-Whitney test. Statistical analysis of binary data was performed using Fisher’s exact test http://www.measuringu.com/ab-calc.php. The logistic model for the dependence of 5‘LTR DNA methylation levels on time was fitted in the statistical software R. Significance of the association was tested by the standard (Wald) test. The corresponding p values are indicated in the figure legends.
DNA methyltransferase 1
DNA methyltransferase 3B
human immunodeficiency virus type 1
long terminal repeat
methyl-CpG binding protein 2
peripheral blood mononuclear cells
RNA polymerase II, polypeptide A
suberoylanilide hydroxamic acid
tumor necrosis factor-α
Our work was supported by grant No. P304/12/1736 from the Czech Science Foundation dedicated to Katerina Trejbalova. The work was also institutionally supported by RVO:68378050 . We thank Philippe Halfon from Department of Virology, Alphabio Laboratory, 13006 Marseille, France.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Chun TW, Engel D, Mizell SB, Hallahan CW, Fischette M, Park S, et al. Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy. Nat Med. 1999;5:651–5.View ArticlePubMedGoogle Scholar
- Davey RT, Bhat N, Yoder C, Chun TW, Metcalf JA, Dewar R, et al. HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. Proc Natl Acad Sci U S A. 1999;96:15109–14.PubMed CentralView ArticlePubMedGoogle Scholar
- Finzi D, Blankson J, Siliciano JD, Margolick JB, Chadwick K, Pierson T, et al. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med. 1999;5:512–7.View ArticlePubMedGoogle Scholar
- Ramratnam B, Mittler JE, Zhang LQ, Boden D, Hurley A, Fang F, et al. The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy. Nat Med. 2000;6:82–5.View ArticlePubMedGoogle Scholar
- VanLint C, Emiliani S, Ott M, Verdin E. Transcriptional activation and chromatin remodeling of the HIV-1 promoter in response to histone acetylation. Embo Journal. 1996;15:1112–20.Google Scholar
- du Chene I, Basyuk E, Lin YL, Triboulet R, Knezevich A, Chable-Bessia C, et al. Suv39H1 and HP1gamma are responsible for chromatin-mediated HIV-1 transcriptional silencing and post-integration latency. Embo J. 2007;26:424–35.PubMed CentralView ArticlePubMedGoogle Scholar
- Marban C, Suzanne S, Dequiedt F, de Walque S, Redel L, Van Lint C, et al. Recruitment of chromatin-modifying enzymes by CTIP2 promotes HIV-1 transcriptional silencing. Embo J. 2007;26:412–23.PubMed CentralView ArticlePubMedGoogle Scholar
- He GC, Margolis DM. Counterregulation of chromatin deacetylation and histone deacetylase occupancy at the integrated promoter of human immunodeficiency virus type 1 (HIV-1) by the HIV-1 repressor YY1 and HIV-1 activator Tat. Mol Cell Biol. 2002;22:2965–73.PubMed CentralView ArticlePubMedGoogle Scholar
- Tyagi M, Karn J. CBF-1 promotes transcriptional silencing during the establishment of HIV-1 latency. Embo J. 2007;26:4985–95.PubMed CentralView ArticlePubMedGoogle Scholar
- Williams SA, Chen LF, Kwon H, Ruiz-Jarabo CM, Verdin E, Greene WC. NF-kappaB p50 promotes HIV latency through HDAC recruitment and repression of transcriptional initiation. Embo J. 2006;25:139–49.PubMed CentralView ArticlePubMedGoogle Scholar
- Keedy KS, Archin NM, Gates AT, Espeseth A, Hazuda DJ, Margolis DM. A limited group of class I histone deacetylases acts to repress human immunodeficiency virus type 1 expression. J Virol. 2009;83:4749–56.PubMed CentralView ArticlePubMedGoogle Scholar
- Jordan A, Bisgrove D, Verdin E. HIV reproducibly establishes a latent infection after acute infection of T cells in vitro. Embo J. 2003;22:1868–77.
- Lusic M, Marini B, Ali H, Lucic B, Luzzati R, Giacca M. Proximity to PML nuclear bodies regulates HIV-1 latency in CD4+ T cells. Cell Host Microbe. 2013;13:665–77.View ArticlePubMedGoogle Scholar
- Karn J. The molecular biology of HIV latency: breaking and restoring the Tat-dependent transcriptional circuit. Curr Opin HIV AIDS. 2011;6:4–11.PubMed CentralView ArticlePubMedGoogle Scholar
- Choudhary SK, Curing MDM, HIV. Pharmacologic approaches to target HIV-1 latency. Annu Rev Pharmacol Toxicol. 2011;51:397–418.PubMed CentralView ArticlePubMedGoogle Scholar
- Hakre S, Chavez L, Shirakawa K, Verdin E. HIV latency: experimental systems and molecular models. Fems Microbiol Rev. 2012;36:706–16.PubMed CentralView ArticlePubMedGoogle Scholar
- Siliciano JD, Lai J, Callender M, Pitt E, Zhang H, Margolick JB, et al. Stability of the latent reservoir for HIV-1 in patients receiving valproic acid. J Infect Dis. 2007;195:833–6.View ArticlePubMedGoogle Scholar
- Sagot-Lerolle N, Lamine A, Chaix ML, Boufassa F, Aboulker JP, Costagliola D, et al. Prolonged valproic acid treatment does not reduce the size of latent HIV reservoir. Aids. 2008;22:1125–9.View ArticlePubMedGoogle Scholar
- Margolis DM. Histone deacetylase inhibitors and HIV latency. Curr Opin HIV AIDS. 2011;6:25–9.PubMed CentralView ArticlePubMedGoogle Scholar
- Routy JP, Tremblay CL, Angel JB, Trottier B, Rouleau D, Baril JG, et al. Valproic acid in association with highly active antiretroviral therapy for reducing systemic HIV-1 reservoirs: results from a multicentre randomized clinical study. HIV Med. 2012;13:291–6.View ArticlePubMedGoogle Scholar
- Archin NM, Bateson R, Tripathy MK, Crooks AM, Yang KH, Dahl NP, et al. HIV-1 expression within resting CD4+ T cells after multiple doses of vorinostat. J Infect Dis. 2014;210:728–35.PubMed CentralView ArticlePubMedGoogle Scholar
- Archin NM, Cheema M, Parker D, Wiegand A, Bosch RJ, Coffin JM, et al. Antiretroviral intensification and valproic acid lack sustained effect on residual HIV-1 viremia or resting CD4+ cell infection. PLoS One. 2010;5, e9390.PubMed CentralView ArticlePubMedGoogle Scholar
- Archin NM, Vaidya NK, Kuruc JD, Liberty AL, Wiegand A, Kearney MF, et al. Immediate antiviral therapy appears to restrict resting CD4+ cell HIV-1 infection without accelerating the decay of latent infection. Proc Natl Acad Sci U S A. 2012;109:9523–8.PubMed CentralView ArticlePubMedGoogle Scholar
- Lehrman G, Hogue IB, Palmer S, Jennings C, Spina CA, Wiegand A, et al. Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. Lancet. 2005;366:549–55.PubMed CentralView ArticlePubMedGoogle Scholar
- Archin NM, Eron JJ, Palmer S, Hartmann-Duff A, Martinson JA, Wiegand A, et al. Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells. Aids. 2008;22:1131–5.View ArticlePubMedGoogle Scholar
- Routy JP, Angel JB, Spaans JN, Trottier B, Rouleau D, Baril JG, et al. Design and implementation of a randomized crossover study of valproic acid and antiretroviral therapy to reduce the HIV reservoir. HIV Clin Trials. 2012;13:301–7.View ArticlePubMedGoogle Scholar
- Archin NM, Espeseth A, Parker D, Cheema M, Hazuda D, Margolis DM. Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid. AIDS Res Hum Retroviruses. 2009;25:207–12.PubMed CentralView ArticlePubMedGoogle Scholar
- Reuse S, Calao M, Kabeya K, Guiguen A, Gatot JS, Quivy V, et al. Synergistic activation of HIV-1 expression by deacetylase inhibitors and prostratin: implications for treatment of latent infection. PLoS One. 2009;4, e6093.PubMed CentralView ArticlePubMedGoogle Scholar
- Blazkova J, Trejbalova K, Gondois-Rey F, Halfon P, Philibert P, Guiguen A, et al. CpG methylation controls reactivation of HIV from latency. Plos Pathogens. 2009;5.
- Archin NM, Liberty AL, Kashuba AD, Choudhary SK, Kuruc JD, Crooks AM, et al. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature. 2012;487:482–5.PubMed CentralView ArticlePubMedGoogle Scholar
- Elliott JH, Wightman F, Solomon A, Ghneim K, Ahlers J, Cameron MJ, et al. Activation of HIV transcription with short-course vorinostat in HIV-infected patients on suppressive antiretroviral therapy. PLoS Pathog. 2014;10, e1004473.PubMed CentralView ArticlePubMedGoogle Scholar
- Blazkova J, Chun TW, Belay BW, Murray D, Justement JS, Funk EK, et al. Effect of histone deacetylase inhibitors on HIV production in latently infected, resting CD4(+) T cells from infected individuals receiving effective antiretroviral therapy. J Infect Dis. 2012;206:765–9.PubMed CentralView ArticlePubMedGoogle Scholar
- Rasmussen TA, Schmeltz Sogaard O, Brinkmann C, Wightman F, Lewin SR, Melchjorsen J, et al. Comparison of HDAC inhibitors in clinical development: effect on HIV production in latently infected cells and T-cell activation. Hum Vaccin Immunother. 2013;9:993–1001.PubMed CentralView ArticlePubMedGoogle Scholar
- Wei DG, Chiang V, Fyne E, Balakrishnan M, Barnes T, Graupe M, et al. Histone deacetylase inhibitor romidepsin induces HIV expression in CD4 T cells from patients on suppressive antiretroviral therapy at concentrations achieved by clinical dosing. Plos Pathogens. 2014;10, e1004071.PubMed CentralView ArticlePubMedGoogle Scholar
- Sogaard OS, Graversen ME, Leth S, Olesen R, Brinkmann CR, Nissen SK, et al. The depsipeptide romidepsin reverses HIV-1 latency in vivo. Plos Pathogens. 2015;11, e1005142.PubMed CentralView ArticlePubMedGoogle Scholar
- Kumar A, Darcis G, Van Lint C, Herbein G. Epigenetic control of HIV-1 post integration latency: implications for therapy. Clinical Epigenetics. 2015;7:103.PubMed CentralView ArticlePubMedGoogle Scholar
- Kauder SE, Bosque A, Lindqvist A, Planelles V, Verdin E. Epigenetic regulation of HIV-1 latency by cytosine methylation. Plos Pathogens. 2009;5.
- Pion M, Jordan A, Biancotto A, Dequiedt F, Gondois-Rey F, Rondeau S, et al. Transcriptional suppression of in vitro-integrated human immunodeficiency virus type 1 does not correlate with proviral DNA methylation. J Virol. 2003;77:4025–32.PubMed CentralView ArticlePubMedGoogle Scholar
- Blazkova J, Murray D, Justement JS, Funk EK, Nelson AK, Moir S, et al. Paucity of HIV DNA methylation in latently infected, resting CD4+ T cells from infected individuals receiving antiretroviral therapy. J Virol. 2012;86:5390–2.PubMed CentralView ArticlePubMedGoogle Scholar
- Ho Y-C, Shan L, Hosmane Nina N, Wang J, Laskey Sarah B, Rosenbloom Daniel IS, et al. Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure. Cell. 2013;155:540–51.PubMed CentralView ArticlePubMedGoogle Scholar
- Palacios JA, Perez-Pinar T, Toro C, Sanz-Minguela B, Moreno V, Valencia E, et al. Long-term nonprogressor and elite controller patients who control viremia have a higher percentage of methylation in their HIV-1 proviral promoters than aviremic patients receiving highly active antiretroviral therapy. J Virol. 2012;86:13081–4.PubMed CentralView ArticlePubMedGoogle Scholar
- Weber S, Weiser B, Kemal KS, Burger H, Ramirez CM, Korn K, et al. Epigenetic analysis of HIV-1 proviral genomes from infected individuals: predominance of unmethylated CpG's. Virology. 2014;449:181–9.PubMed CentralView ArticlePubMedGoogle Scholar
- Castagna M, Takai Y, Kaibuchi K, Sano K, Kikkawa U, Nishizuka Y. Direct activation of calcium-activated, phospholipid-dependent protein kinase by tumor-promoting phorbol esters. J Biol Chem. 1982;257:7847–51.PubMedGoogle Scholar
- Duh EJ, Maury WJ, Folks TM, Fauci AS, Rabson AB. Tumor necrosis factor alpha activates human immunodeficiency virus type 1 through induction of nuclear factor binding to the NF-kappa B sites in the long terminal repeat. Proc Natl Acad Sci U S A. 1989;86:5974–8.PubMed CentralView ArticlePubMedGoogle Scholar
- Osborn L, Kunkel S, Nabel GJ. Tumor necrosis factor alpha and interleukin 1 stimulate the human immunodeficiency virus enhancer by activation of the nuclear factor kappa B. Proc Natl Acad Sci U S A. 1989;86:2336–40.PubMed CentralView ArticlePubMedGoogle Scholar
- Hernando-Herraez I, Garcia-Perez R, Sharp AJ, Marques-Bonet T. DNA methylation: insights into human evolution. PLoS Genet. 2015;11, e1005661.PubMed CentralView ArticlePubMedGoogle Scholar
- Pinkevych M, Cromer D, Tolstrup M, Grimm AJ, Cooper DA, Lewin SR, et al. HIV reactivation from latency after treatment interruption occurs on average every 5-8 days—implications for HIV remission. PLoS Pathog. 2015;11, e1005000.PubMed CentralView ArticlePubMedGoogle Scholar
- Shan L, Deng K, Shroff NS, Durand CM, Rabi SA, Yang HC, et al. Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation. Immunity. 2012;36:491–501.PubMed CentralView ArticlePubMedGoogle Scholar
- Siliciano RF, Greene WC. HIV latency. Cold Spring Harb Perspect Med. 2011;1:a007096.PubMed CentralView ArticlePubMedGoogle Scholar
- Lassen K, Han Y, Zhou Y, Siliciano J, Siliciano RF. The multifactorial nature of HIV-1 latency. Trends Mol Med. 2004;10:525–31.View ArticlePubMedGoogle Scholar
- Rodriguez RM, Suarez-Alvarez B, Mosen-Ansorena D, Garcia-Peydro M, Fuentes P, Garcia-Leon MJ, et al. Regulation of the transcriptional program by DNA methylation during human alphabeta T-cell development. Nucleic Acids Res. 2015;43:760–74.PubMed CentralView ArticlePubMedGoogle Scholar
- Hashimoto S, Ogoshi K, Sasaki A, Abe J, Qu W, Nakatani Y, et al. Coordinated changes in DNA methylation in antigen-specific memory CD4 T cells. J Immunol. 2013;190:4076–91.PubMed CentralView ArticlePubMedGoogle Scholar
- Komori HK, Hart T, LaMere SA, Chew PV, Salomon DR. Defining CD4 T cell memory by the epigenetic landscape of CpG DNA methylation. J Immunol. 2015;194:1565–79.PubMed CentralView ArticlePubMedGoogle Scholar
- Li Y, Chen G, Ma L, Ohms SJ, Sun C, Shannon MF, et al. Plasticity of DNA methylation in mouse T cell activation and differentiation. BMC Mol Biol. 2012;13:16.PubMed CentralView ArticlePubMedGoogle Scholar
- Li Y, Ohms SJ, Shannon FM, Sun C, Fan JY. IL-2 and GM-CSF are regulated by DNA demethylation during activation of T cells, B cells and macrophages. Biochem Biophys Res Commun. 2012;419:748–53.View ArticlePubMedGoogle Scholar
- Bruniquel D, Schwartz RH. Selective, stable demethylation of the interleukin-2 gene enhances transcription by an active process. Nat Immunol. 2003;4:235–40.View ArticlePubMedGoogle Scholar
- Dong J, Chang HD, Ivascu C, Qian Y, Rezai S, Okhrimenko A, et al. Loss of methylation at the IFNG promoter and CNS-1 is associated with the development of functional IFN-gamma memory in human CD4(+) T lymphocytes. Eur J Immunol. 2013;43:793–804.View ArticlePubMedGoogle Scholar
- Maricato JT, Furtado MN, Takenaka MC, Nunes ER, Fincatti P, Meliso FM, et al. Epigenetic modulations in activated cells early after HIV-1 infection and their possible functional consequences. PLoS One. 2015;10, e0119234.PubMed CentralView ArticlePubMedGoogle Scholar
- Klose RJ, Bird AP. Genomic DNA methylation: the mark and its mediators. Trends Biochem Sci. 2006;31:89–97.View ArticlePubMedGoogle Scholar
- Baubec T, Ivanek R, Lienert F, Schubeler D. Methylation-dependent and -independent genomic targeting principles of the MBD protein family. Cell. 2013;153:480–92.View ArticlePubMedGoogle Scholar
- Pandiyan K, You JS, Yang X, Dai C, Zhou XJ, Baylin SB, et al. Functional DNA demethylation is accompanied by chromatin accessibility. Nucleic Acids Res. 2013;41:3973–85.PubMed CentralView ArticlePubMedGoogle Scholar
- Marchi E, Zullo KM, Amengual JE, Kalac M, Bongero D, McIntosh CM, et al. The combination of hypomethylating agents and histone deacetylase inhibitors produce marked synergy in preclinical models of T-cell lymphoma. Br J Haematol. 2015;171:215–226.
- Hou L, Ma F, Yang J, Riaz H, Wang Y, Wu W, et al. Effects of histone deacetylase inhibitor oxamflatin on in vitro porcine somatic cell nuclear transfer embryos. Cell Reprogram. 2014;16:253–65.PubMed CentralView ArticlePubMedGoogle Scholar
- Gu S, Tian Y, Chlenski A, Salwen HR, Lu Z, Raj JU, et al. Valproic acid shows a potent antitumor effect with alteration of DNA methylation in neuroblastoma. Anticancer Drugs. 2012;23:1054–66.PubMed CentralView ArticlePubMedGoogle Scholar
- Liu Y, Mayo MW, Nagji AS, Smith PW, Ramsey CS, Li D, et al. Phosphorylation of RelA/p65 promotes DNMT-1 recruitment to chromatin and represses transcription of the tumor metastasis suppressor gene BRMS1. Oncogene. 2012;31:1143–54.PubMed CentralView ArticlePubMedGoogle Scholar
- Acharyya S, Sharma SM, Cheng AS, Ladner KJ, He W, Kline W, et al. TNF inhibits Notch-1 in skeletal muscle cells by Ezh2 and DNA methylation mediated repression: implications in duchenne muscular dystrophy. PLoS One. 2010;5, e12479.PubMed CentralView ArticlePubMedGoogle Scholar
- Pacaud R, Sery Q, Oliver L, Vallette FM, Tost J, Cartron PF. DNMT3L interacts with transcription factors to target DNMT3L/DNMT3B to specific DNA sequences: role of the DNMT3L/DNMT3B/p65-NFkappaB complex in the (de-)methylation of TRAF1. Biochimie. 2014;104:36–49.View ArticlePubMedGoogle Scholar
- Dunican DS, Cruickshanks HA, Suzuki M, Semple CA, Davey T, Arceci RJ, et al. Lsh regulates LTR retrotransposon repression independently of Dnmt3b function. Genome Biol. 2013;14:R146.PubMed CentralView ArticlePubMedGoogle Scholar
- Li Z, Dai H, Martos SN, Xu B, Gao Y, Li T, et al. Distinct roles of DNMT1-dependent and DNMT1-independent methylation patterns in the genome of mouse embryonic stem cells. Genome Biol. 2015;16:115.PubMed CentralView ArticlePubMedGoogle Scholar
- Senigl F, Auxt M, Hejnar J. Transcriptional provirus silencing as a crosstalk of de novo DNA methylation and epigenomic features at the integration site. Nucleic Acids Res. 2012;40:5298–312.PubMed CentralView ArticlePubMedGoogle Scholar
- Dhayalan A, Rajavelu A, Rathert P, Tamas R, Jurkowska RZ, Ragozin S, et al. The Dnmt3a PWWP domain reads histone 3 lysine 36 trimethylation and guides DNA methylation. J Biol Chem. 2010;285:26114–20.PubMed CentralView ArticlePubMedGoogle Scholar
- Kolasinska-Zwierz P, Down T, Latorre I, Liu T, Liu XS, Ahringer J. Differential chromatin marking of introns and expressed exons by H3K36me3. Nat Genet. 2009;41:376–81.PubMed CentralView ArticlePubMedGoogle Scholar
- Chomont N, El-Far M, Ancuta P, Trautmann L, Procopio FA, Yassine-Diab B, et al. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat Med. 2009;15:893–900.PubMed CentralView ArticlePubMedGoogle Scholar
- Bosque A, Famiglietti M, Weyrich AS, Goulston C, Planelles V. Homeostatic proliferation fails to efficiently reactivate HIV-1 latently infected central memory CD4+ T cells. Plos Pathogens. 2011;7, e1002288.PubMed CentralView ArticlePubMedGoogle Scholar
- von Stockenstrom S, Odevall L, Lee E, Sinclair E, Bacchetti P, Killian M, et al. Longitudinal genetic characterization reveals that cell proliferation maintains a persistent HIV type 1 DNA pool during effective HIV therapy. J Infect Dis. 2015;212:596–607.View ArticleGoogle Scholar
- Maldarelli F, Wu X, Su L, Simonetti FR, Shao W, Hill S, et al. HIV latency. Specific HIV integration sites are linked to clonal expansion and persistence of infected cells. Science. 2014;345:179–83.PubMed CentralView ArticlePubMedGoogle Scholar
- Wagner TA, McLaughlin S, Garg K, Cheung CY, Larsen BB, Styrchak S, et al. HIV latency. Proliferation of cells with HIV integrated into cancer genes contributes to persistent infection. Science. 2014;345:570–3.PubMed CentralView ArticlePubMedGoogle Scholar
- Cohn LB, Silva IT, Oliveira TY, Rosales RA, Parrish EH, Learn GH, et al. HIV-1 integration landscape during latent and active infection. Cell. 2015;160:420–32.PubMed CentralView ArticlePubMedGoogle Scholar
- Weinberger Ariel D, Weinberger LS. Stochastic fate selection in HIV-infected patients. Cell. 2013;155:497–9.View ArticlePubMedGoogle Scholar
- Jordan A, Defechereux P, Verdin E. The site of HIV-1 integration in the human genome determines basal transcriptional activity and response to Tat transactivation. Embo J. 2001;20:1726–38.PubMed CentralView ArticlePubMedGoogle Scholar